Extrait

The primary objective of the study is to evaluate the PK of perampanel during the Maintenance Period of the Core Study following oral suspension administration given as an adjunctive therapy in pediatric subjects from 1 month to less than 24 months (<2 years) of age with epilepsy.

Critère d'inclusion

• This study is to investigate the pharmacokinetics (PK) of perampanel in pediatric subjects from age ≥1 to <24 months (<2 years)

Liens

• euctr